Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.
about
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesBiomarkers in vasculitisDye-doped silica nanoparticle labels/protein microarray for detection of protein biomarkersInterleukin-1 beta induction of neuron apoptosis depends on p38 mitogen-activated protein kinase activity after spinal cord injuryUpdate on the management of giant cell arteritis.Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.The promotion of functional urinary bladder regeneration using anti-inflammatory nanofibersImmune mechanisms in medium and large-vessel vasculitis.Unexpected Inflammatory Effects of Intravaginal Gels (Universal Placebo Gel and Nonoxynol-9) on the Upper Female Reproductive Tract: A Randomized Crossover Study.Effects of Omega-3-Rich Harp Seal Oil on the Production of Pro-Inflammatory Cytokines in Mouse Peritoneal MacrophagesTocilizumab reverses cerebral vasculopathy in a patient with homozygous SAMHD1 mutation.Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell ArteritisProinflammatory cytokines and matrix metalloproteinases in CSF of patients with VZV vasculopathyBiologic Therapy for the Treatment of Giant Cell Arteritis.Current understanding and management of giant cell arteritis and polymyalgia rheumatica.New indications for biological therapies.Clinical features of polymyalgia rheumatica and giant cell arteritis.Genetic component of giant cell arteritis.Tocilizumab: a new therapy for large vessel vasculitis.DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis.New insights into the pathogenesis of giant cell arteritis and hopes for the clinic.Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study.Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.Giant Cell Arteritis - Beyond temporal artery biopsy and steroids.Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling.Gelatinase expression and proteolytic activity in giant-cell arteritis.Regulation of Inflammation and Angiogenesis in Giant Cell Arteritis by Acute-Phase Serum Amyloid A.Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis.Successful treatment of refractory giant cell arteritis with etanercept.An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.Expression of Surfactant Protein-A during LPS-Induced Otitis Media with Effusion in Mice.Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis.The Treatment of Giant Cell Arteritis.Investigational drugs in systemic vasculitis.Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis.Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemiaAssociation of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genesInfluence of theIL17A locusin giant cell arteritis susceptibility
P2860
Q26799747-3AA9B682-86B2-4573-9493-0F4B7428B418Q26825345-11A732ED-62B4-4976-B259-879D43D44DEEQ28386535-A4D01663-4E68-4AC7-A002-A233DE20186BQ28572380-77D8C300-BA4E-4141-947D-FB58D09ED7EFQ33605954-5C1A408D-8F0D-4672-A013-6080149D8498Q34346251-88D4B3AF-8FD6-4088-A97E-E6A532F9E59CQ34722403-4D66EA90-9F1C-4B59-BEA5-1FB0F265C089Q34777943-375CDF65-99B2-4220-9AF6-ED344D8081B2Q35692556-31A01362-EB62-4079-BDD8-0C2E48148A47Q35846589-A80F6E82-BA8C-4879-B8D0-712FBA0C48DCQ36307015-9018FA6E-6F88-4229-800F-F6E2E98D0BDCQ36653502-758C57FD-BE1C-4009-8E8A-753C8D29D7C8Q37004065-16C92A99-084F-4F5E-906D-A538E1C0FA24Q37439687-2880C7A3-6A2B-4552-B458-821807CBF1BBQ37803414-F9003C8C-E81B-4DFE-B21D-16684A3F10DEQ37947157-09CB6E5A-9763-4CA2-8F9E-EAE74FFAAA1FQ38028863-081878DB-4627-4F75-A6EA-DFA1CDBA4CD6Q38120699-8DF59D3F-206A-4F10-A0DF-2566EA51B409Q38129269-95A6C52C-1D13-4054-A3B9-ACFE9717F678Q38462330-E8FC9225-1DD6-44D9-B110-9F0C9A35A289Q38586408-438CD32A-6B03-4B91-840D-3DD882915DA9Q38787301-95B81143-FBE4-46AE-BD46-E56CF7FED92DQ39100312-4D1036AC-3D9D-45AB-9592-CA331275B9DEQ39293033-6056BB5B-AA10-4ABB-B4C9-217D2E1338EFQ39918063-C39C709E-299D-4813-AE35-E191361090CFQ41348284-6541B356-9455-4321-B747-A40483EEC48DQ42477536-EB71057F-25E9-48D0-A06A-0FC70386C65CQ43035849-D9AAB5BF-EDFD-4838-84C2-85A56056DA4FQ45034871-5B99167B-7024-423C-94ED-9FE2D5D487E1Q48178113-A7C0F6C4-1747-497C-97A6-5B770059F504Q49369622-CA6A241F-108F-4745-A799-93C12FB7B565Q50547686-062B673F-52E8-46CD-A512-B0F5E5C1F03DQ51033475-BC5C0B1D-0B5C-4299-9C30-7CE050419398Q51161072-5755173C-B923-4CB5-925A-3ADBB4CAD852Q51834131-B8F4676A-6827-4A43-9546-75C3654024DDQ52893205-DD95E331-8659-4FB8-B9E3-A4D710EA0C98Q54943677-B89F53FC-693A-4789-93E6-6D54B8D0EABDQ56942323-4C890B17-B719-401A-8290-EA4B27281C21Q57279273-B31574B7-1469-45BF-B6A2-02AD1B64E227Q57307049-C00D68AA-7844-4400-8FA7-C35D21980E0D
P2860
Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Tissue production of pro-infla ...... ments in giant-cell arteritis.
@en
Tissue production of pro-infla ...... ments in giant-cell arteritis.
@nl
type
label
Tissue production of pro-infla ...... ments in giant-cell arteritis.
@en
Tissue production of pro-infla ...... ments in giant-cell arteritis.
@nl
prefLabel
Tissue production of pro-infla ...... ments in giant-cell arteritis.
@en
Tissue production of pro-infla ...... ments in giant-cell arteritis.
@nl
P2093
P356
P1433
P1476
Tissue production of pro-infla ...... ments in giant-cell arteritis.
@en
P2093
Esteban MJ
García-Martínez A
Hernández-Rodríguez J
Urbano-Márquez A
P304
P356
10.1093/RHEUMATOLOGY/KEH058
P577
2003-12-16T00:00:00Z